NCT03333928已完成2 期
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 50
- 主要终点
- Absolute Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 6 in Period 1
研究概览
简要总结
The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female between 18 and 75 years of age;
- •Have a clinical diagnosis of PSC as evident by chronic cholestasis of more than six months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis;
- •If subjects have Inflammatory Bowel Disease (IBD) they will be eligible to participate. If a subject has IBD, documented evidence of IBD must have been evident by prior endoscopy or in previous medical records for ≥6 months. In addition, subjects may only enter the study with a Partial Mayo Score of 0-4, inclusively. Subjects who are on treatment are allowed, provided they are stable for 3 months if taking:
- •5-amino salicylic acid drugs,
- •azathioprine,
- •6-mercaptopurine, or methotrexate
- •Have a serum ALP ≥1.5 × upper limit of normal (ULN);
- •Be able to understand and sign a written informed consent form (ICF);
- •Subjects receiving allowed concomitant medications need to be on stable therapy for 28 days prior to the Baseline visit, with the exception of ursodeoxycholic acid (UDCA), which should be stable for at least 6 weeks prior to the Baseline visit.
排除标准
- •Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis) on prior clinical investigations;
- •Small duct PSC;
- •Presence of percutaneous drain or bile duct stent;
- •History of cholangiocarcinoma or clinical suspicion of new dominant stricture within 1 year by MRCP/ERCP. Presence of dominant stricture without ERCP evidence of cholangiocarcinoma is acceptable if stable for ≥ 1 year;
- •Ascending cholangitis within 60 days prior to Screening;
- •History of alcohol or substance abuse or dependence;
- •Prior or planned liver transplantation;
- •Presence of alternative causes of chronic liver disease, including alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis;
- •Platelet count below 125,000/mm3, albumin below 3.0 g/dL, International Normalized Ratio (INR) > 1.2, or a history of ascites, or encephalopathy, or history of esophageal variceal bleeding;
- •Severe active IBD or flare in colitis activity within the last 90 days requiring intensification of therapy beyond baseline treatment;
研究组 & 干预措施
HTD1801 500 mg BID
Active Comparator
干预措施: HTD1801 (Drug)
HTD1801 1000 mg BID
Active Comparator
干预措施: HTD1801 (Drug)
Placebo BID
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Absolute Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 6 in Period 1
时间窗: Baseline to Week 6
次要结局
- Percentage of Subjects Who Achieve ALP of <1.5 x ULN at the End of Week 6 (Period 1)(Baseline to Week 6)
- Percentage of Patients Who Normalize ALP at the End of Week 12 (Period 2)(Week 6 to Week 12)
- Percentage of Subjects Who Normalize ALP at the End of Week 6 (Period 1)(Baseline to Week 6)
- Percentage of Subjects Who Achieve ALP of <1.5 x ULN at the End of Week 12 (Period 2)(Week 6 to Week 12)
- Percentage of Subjects Who Normalize ALP at the End of Week 18 (Period 3)(Week 12 to Week 18)
- Percentage of Subjects Who Achieve a 50% Decrease in ALP at the End of Week 6 (Period 1)(Baseline to Week 6)
- Absolute Change in Serum ALP From Week 6 to Week 12 (Period 2)(Week 6 to Week 12)
- Percentage of Patients Who Achieve a 50% Decrease in ALP at the End of Week 12 (Period 2)(Week 6 to Week 12)
- Percentage of Patients Who Achieve ALP of <1.5 x ULN at the End of Week 18 (Period 3)(Week 12 to Week 18)
- Absolute Change in Serum ALP From Week 12 to Week 18 (Period 3)(Week 12 to Week 18)
- Absolute Change in Serum Total Bilirubin at the End of Week 18 (Period 3)(Week 12 to Week 18)
- Absolute Change in Serum Total Bilirubin at the End of Week 6 (Period 1)(Baseline to Week 6)
- Absolute Change in Serum Total Bilirubin at the End of Week 12 (Period 2)(Week 6 to Week 12)
- Percentage of Patients Who Achieve a 50% Decrease in ALP at the End of Week 18 (Period 3)(Week 12 to Week 18)
研究者
研究点 (50)
Loading locations...
相似试验
已完成
2 期
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)Fatty Liver, NonalcoholicNonalcoholic SteatohepatitisDigestive System DiseasesType 2 Diabetes Mellitus (T2DM)Nonalcoholic Fatty Liver DiseaseNAFLDNCT03656744HighTide Therapeutics (Hong Kong) Limited101
进行中（未招募）
2 期
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With DemodexDemodex Infestation of EyelidDemodectic BlepharitisBlepharitisMeibomian Gland DysfunctionNCT06054217Tarsus Pharmaceuticals, Inc.36
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety DisorderGeneralized AnxietyNCT00390533Sanofi428
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult WomenNocturiaNCT01684800Ferring Pharmaceuticals178
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult MenNocturiaNCT01694498Ferring Pharmaceuticals183